Targeting KRAS in Colorectal Cancer

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting KRAS in colorectal cancer.

Clinical Pearls

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targetingKRASin colorectal cancer.

  • KRASis mutated in 40% of patients and defines who should get cetuximab or panitumumab
  • Patients should be genotyped for all mutations inKRASandNRAS
  • Defining drug targets against mutantKRAShas been impossible thus far